Literature DB >> 24074771

Close/positive margins after breast-conserving therapy: additional resection or no resection?

William C Wood1.   

Abstract

The primary goal of breast conserving surgery or mastectomy is the prevention of recurrent breast cancer. The distinguishing goal of breast conserving surgery is preservation of a breast as normal in appearance as possible. If the margins of the excised breast cancer extend to the border of the excised specimen one cannot determine the amount of gross tumor that was not excised. Retrospective analyses of surgical series show a 2-3 fold increase in local recurrence of the breast tumor if the margin is positive under the microscope, even when the surgeon believed it to be clear on gross examination. This fact has led to a variety of techniques attempting to ensure that the margins of the excised specimen are free of obvious tumor including pre-operative and specimen imaging and mapping, neo-adjuvant therapy to shrink the primary tumor, touch-prep and frozen section of the specimen margins during the procedure, shaving additional margins about the specimen at the closest aspects grossly or on all six surfaces, and examinations of the in situ walls of the remaining breast with new instrumentation. An obvious approach to diminishing the likelihood of positive specimen margins is taking a wider margin of normal tissue. As the volume of resected breast increases by the cube of the radius of excised tissue, this tracks all too well with diminishing cosmetic results and patient approval of the conserved breast. The question posed regards the finding of a positive or close margin after the surgical procedure. The finding of a positive margin can be parsed to a microscopic focus of tumor at the margin vs. the margin inking on a tumor surface. The latter demands re-excision despite the morbidity involved barring an extraordinary contra-indication or patient refusal. It represents the very real possibility of sufficient residual gross tumor in the breast that even with systemic therapy and breast irradiation the tumor will be un-controlled. A microscopic focus separated from the bulk of the primary tumor and adjacent to a margin has not been shown to carry such risk. The margin of normal tissue beyond the primary tumor that significantly reduces the risk of local recurrence remains undefined. Sufficient data are available to say that in the era of systemic therapy, excellent radiation therapy techniques, and boost doses when indicated, no margin of normal breast tissue beyond the tumor has been shown to be clearly superior to a layer of cells between the ink and the tumor. The larger the tumor and the more aggressive its biology is judged to be the lower the confidence that a single layer of cells at the point of histologic study accurately represents a clear margin. As in all medical decisions wise judgment must integrate all of the known factors to reach the best recommendation. There are few circumstances that would warrant a second surgical procedure for a close but clear margin today.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Breast conserving therapy; Margins; Re-excision

Mesh:

Year:  2013        PMID: 24074771     DOI: 10.1016/j.breast.2013.07.022

Source DB:  PubMed          Journal:  Breast        ISSN: 0960-9776            Impact factor:   4.380


  9 in total

1.  Tissue-simulating phantoms for assessing potential near-infrared fluorescence imaging applications in breast cancer surgery.

Authors:  Rick Pleijhuis; Arwin Timmermans; Johannes De Jong; Esther De Boer; Vasilis Ntziachristos; Gooitzen Van Dam
Journal:  J Vis Exp       Date:  2014-09-19       Impact factor: 1.355

2.  Androgen and oestrogen receptors as potential prognostic markers for patients with ductal carcinoma in situ treated with surgery and radiotherapy.

Authors:  Sara Ravaioli; Maria Maddalena Tumedei; Flavia Foca; Roberta Maltoni; Andrea Rocca; Ilaria Massa; Elisabetta Pietri; Sara Bravaccini
Journal:  Int J Exp Pathol       Date:  2017-11-28       Impact factor: 1.925

Review 3.  Phyllodes tumours of the breast: a consensus review.

Authors:  Benjamin Y Tan; Geza Acs; Sophia K Apple; Sunil Badve; Ira J Bleiweiss; Edi Brogi; José P Calvo; David J Dabbs; Ian O Ellis; Vincenzo Eusebi; Gelareh Farshid; Stephen B Fox; Shu Ichihara; Sunil R Lakhani; Emad A Rakha; Jorge S Reis-Filho; Andrea L Richardson; Aysegul Sahin; Fernando C Schmitt; Stuart J Schnitt; Kalliopi P Siziopikou; Fernando A Soares; Gary M Tse; Anne Vincent-Salomon; Puay Hoon Tan
Journal:  Histopathology       Date:  2016-01       Impact factor: 5.087

4.  [Conservative treatment of breast cancer: experience of a Tunisian team].

Authors:  Kaouther Dimassi; Anissa Gharsa; Mohammed Badis Chanoufi; Ezzeddine Sfar; Dalenda Chelli
Journal:  Pan Afr Med J       Date:  2014-10-15

5.  A priori Prediction of Neoadjuvant Chemotherapy Response and Survival in Breast Cancer Patients using Quantitative Ultrasound.

Authors:  Hadi Tadayyon; Lakshmanan Sannachi; Mehrdad J Gangeh; Christina Kim; Sonal Ghandi; Maureen Trudeau; Kathleen Pritchard; William T Tran; Elzbieta Slodkowska; Ali Sadeghi-Naini; Gregory J Czarnota
Journal:  Sci Rep       Date:  2017-04-12       Impact factor: 4.379

Review 6.  Is invasion a necessary step for metastases in breast cancer?

Authors:  Steven A Narod; Victoria Sopik
Journal:  Breast Cancer Res Treat       Date:  2018-01-20       Impact factor: 4.872

7.  Cost-Effectiveness Analysis of Intraoperative Frozen Section in Women with Breast Cancer: Evidence from South of Iran.

Authors:  Navid Omidifar; Elham Chogani; Vahid Zangouri; Khosro Keshavarz; Abdolrasoul Talei
Journal:  Iran J Med Sci       Date:  2022-03

Review 8.  Robotic-Assisted Surgery for the Treatment of Breast and Cervical Cancers.

Authors:  John P Micha; Mark A Rettenmaier; Randy D Bohart; Bram H Goldstein
Journal:  JSLS       Date:  2022 Apr-Jun       Impact factor: 1.789

9.  Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013.

Authors:  A Goldhirsch; E P Winer; A S Coates; R D Gelber; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2013-08-04       Impact factor: 32.976

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.